




北京协和医院
PEKING UNION MEDICAL COLLEGE HOSPITAL

Bench to bedside: translational nuclear medicine research and clinical theranostics in PUMCH

Pro. Li Huo,
Director of Nuclear medicine department,
Peking Union Medical College Hospital, Beijing, China.

The 23rd International Conference on Cyclotrons and their Applications (CYC2022)
Dec., 5-9, 2022, on-line

- **Peking Union Medical College Hospital** was founded by the Rockefeller Foundation in 1921.
- Over the past 100 years, PUMCH has been leading the advances of modern medical sciences in China, and being ranked 1 in the nation since 2009 to 2022.
- **PUMCH motto: Precision, Perseverance, Diligence, and devotion**




Nuclear Medicine in PUMCH



Faculties and staffs of NM (2021)


- Nuclear Medicine department was founded in **1958**
- Equipment for imaging: 2 PET/MR, 5 PET/CT, 8 SPECT/CT and 2 SPECT. Equipment for radiopharmaceutical synthesis and research: 1 Cyclotron, 1 Micro PET, 2 Generator (^{99}Mo - $^{99\text{m}}\text{Tc}$ / ^{68}Ge - ^{68}Ga) and 10 hot cell.
- 1 ward(10beds) for radionuclide therapy
- More than 50 research projects
- More than 10 isotopes and 90 radiopharmaceuticals are employed to support clinical and research work.
- **Ranked 1# in in all China's NM department since 2015 to 2022.**

including secretaries, research staffs,
visiting scholars, Ph.D and Post Doc



Clinical work per year in NM department (case)

	2019	2020	2021	2022 (1-10)
PET scan	11127	9248	12871	10678
SPECT scan	23248	17250	21406	17056
Nuclide therapy	4245	2189	3722	2619
radioimmunoassay	64681	39993	60432	44452
^{13}C breath test	66228	29006	53836	46226



Director: Pro. Huo Li





Radiopharmaceuticals for clinical and research imaging

	^{18}F (Since 1998)		^{68}Ga (Since 2012)	$^{99\text{m}}\text{Tc}$ (Since 1980s)	$^{13}\text{N}/^{11}\text{C}$ (Since 1998)	^{131}I (Since 1958)
1	^{18}F -FDG	^{18}F -FES	^{68}Ga -DOTA-TATE	$^{99\text{m}}\text{Tc}$ -DTPA	^{13}N Ammonia	^{131}I
2	(S)- ^{18}F -FBFP	^{18}F -FEL	^{68}Ga -DOTA-RGD	$^{99\text{m}}\text{Tc}$ -MAA	^{11}C Acetate	^{131}I -MIBG
3	L-5-(2-[^{18}F]fluoro ethoxy)tryptophan	^{18}F -FECH	^{68}Ga -DOTA-EB	$^{99\text{m}}\text{Tc}$ -MDP	^{11}C Choline	
4	Al ^{18}F -PSMA-617	^{18}F -FDS	^{68}Ga -NOTA-PRGD2	$^{99\text{m}}\text{Tc}$ -MIBI	^{11}C Methonine	
5	Al ^{18}F -NOTA-LM3	^{18}F -FDDNP	^{68}Ga -NEB	$^{99\text{m}}\text{Tc}$ -OCT	^{11}C - β -CFT	
6	Al ^{18}F -NOTA-FAPI-04	^{18}F -FCH	^{68}Ga -DOTA-Nerotension	$^{99\text{m}}\text{Tc}$ -SC	^{11}C -PIB	
7	^{18}F -Fluoroacetate	^{18}F -Fallypride	^{68}Ga -BMV101	$^{99\text{m}}\text{Tc}$ -PYP	^{11}C -HFC	
8	^{18}F - β -CFT	^{18}F -DPA-714	^{68}Ga -CXCR4	$^{99\text{m}}\text{Tc}$ -ECD		
9	^{18}F -XTR004	^{18}F -BPA	^{68}Ga -DOTA-TATE-RGD	$^{99\text{m}}\text{Tc}$ -HIDA		
10	^{18}F -T807 (Fluorine-18 flortaucipir)	^{18}F -AV45 (Fluorine-18 florbetapir)	^{68}Ga -DOTA-EB-TATE	$^{99\text{m}}\text{Tc}$ -DMSA		
11	^{18}F -SFB-VEGF	^{18}F -AV1 (Fluorine-18 florbetaben)	^{68}Ga -DOTA-BBN-RGD	$^{99\text{m}}\text{Tc}$ -HSA		
12	^{18}F -P1OP	^{18}F -Al-NOTA-TATE	^{68}Ga -DOTA-TMVP1	$^{99\text{m}}\text{Tc}$ -GSA		
13	^{18}F -MK6240	^{18}F -Al-NOTA-PRGD2	^{68}Ga -exendin4	$^{99\text{m}}\text{Tc}$ -RGD		
14	^{18}F -MFBG	^{18}F -Al-NOTA-EB	^{68}Ga -R01	$^{99\text{m}}\text{Tc}$ -CNDG		
15	^{18}F -L-DOPA	^{18}F -92	^{68}Ga -JR11	$^{99\text{m}}\text{Tc}$ -FAPI		
16	^{18}F -FP-CIT	^{18}F -1799	^{68}Ga -FAPI	$^{99\text{m}}\text{Tc}$ -H-PoFP ₂		
17	^{18}F -FPA	^{18}F -MK6240	^{68}Ga -PSMA			
18	^{18}F -FMISO	^{18}F -FP-CIT	^{68}Ga -DOTA-LM3			
19	^{18}F -FLT	^{18}F -FET	^{68}Ga -RM26			
20	^{18}F -FHBG		^{68}Ga -FSDD ₃ I			
21			^{68}Ga -3BP-227			



Radiopharmaceuticals for clinical and research therapy

- For preclinical research: ^{188}Re , ^{89}Zr , ^{64}Cu , and ^{86}Y .
- For radionuclide therapy:

^{131}I	^{177}Lu (Since 2017)	^{90}Y (Since 2002)	^{89}Sr	^{223}Ra	^{32}P
^{131}I -MIBG	^{177}Lu -PSMA	^{90}Y -TATE			
^{131}I	^{177}Lu -EB-PSMA				
	^{177}Lu -TATE				
	^{177}Lu -EB-TATE				



Whole-body microPET/CT imaging of ^{89}Zr -oxine EPCs in health rats.




- Ding, Jie; et al. ^{86}Y -Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer Diagnosis. *Molecular Pharmaceutics*, 2022, 19(9): 3429-3438.
- Hu Guilan, et al. Development and comparison of three (^{89}Zr)-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study. *Eur J Nucl Med Mol Imaging*, 2022, 49(8): 2634-2644.
- 42. Yimin Liu; et al; Evidence of accumulated endothelial progenitor cells in the lungs of rats with pulmonary arterial hypertension by ^{89}Zr -oxine PET imaging, *Molecular Therapy-Methods & Clinical Development*, 2020. May 3;17:1108-1117


NM translational research stay ahead of the NET theranostic curve

Series translational nuclear medicine research on somatostatin receptor


^{111}In -DTPA-D-Phe¹-octreotide (1996)




$^{99\text{m}}\text{Tc}$ -HYNIC-TOC (2001)



^{68}Ga -DOTATATE (2010)




^{68}Ga -DOTA-JR11 (2018)




^{90}Y -TATE (2002)


Unique in China:
 $^{99\text{m}}\text{Tc}$ -HYNIC-TOC scan guiding PRRT of ^{90}Y -TATE



^{177}Lu -DOTATATE (2017)




Representative images of a 62y-old male patient at 2, 24, 72, 120 and 168h after intravenous administration of ^{177}Lu -DOTA-EB-TATE (19.5mCi)



^{68}Ga -DOTA-TATE PET/CT监测 ^{177}Lu -DOTATATE治疗疗效


NM translational research stay ahead of the NET theranostic curve



2020年第6期 Featured article and cover image


FEATURED ARTICLE

Head-to-Head Comparison of ^{68}Ga -DOTA-JR11 and ^{68}Ga -DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study. Wenjia Zhu et al. See page 897.



Targeting glucose uptake-associated genes: ^{18}F -FDG PET and low-PSMA tumors in prostate cancer. Martin K. Bakke et al. See page 904.


Leading in crisis: looking at the COVID-19 challenges and strategies in a large U.S. health enterprise. Johannes Spann and Johannes Grottel. See page 777.



2021年第10期 Featured article and cover image


FEATURED ARTICLE

A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of ^{68}Ga -NODAGA-LM3 and ^{68}Ga -DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors. Wenjia Zhu et al. See page 1398.



PSMA hybrid molecules: creating a second generation of PSMA-11 agents with enhanced pharmacokinetics and imaging capabilities. Ann-Christin Eder et al. See page 1461.

^{68}Ga -DOTA-JR11 (2018)







Translational medicine is critical for complex severe and rare diseases.

PUMCH, national center for complex, severe and rare diseases



- Pro. Xiaoqian Zhang , famous professor and internist in China.
- He diagnosed the first case of tumor-induced osteomalacia (TIO) in China, a rare paraneoplastic syndrome clinically characterized by bone pain, fractures and muscle weakness.
- TIO lesions are typically small, benign mesenchymal tumors that may be found in bone or soft tissue, anywhere in the body. Locating the tumor is critical, as complete removal is curative.
- However, localization of the lesion is challenging. Only 30% are superficial and can be palpated, while the remaining 70% are impalpable.
- Step wise locating of the culprit lesions is critical for the patients with TIO

SSTR2 imaging help localize TIO




68Ga-DOTATATE PET (+) FDG (-)

68Ga-DOTATATE PET (+)


99mTc-TOC (-)

FDG (-) 68Ga-DOTATATE PET (+)

SSTR2 imaging help localize TIO



99mTc-HYNIC-TOC SPECT imaging




⁶⁸Ga-DOTATATE PET (+) FDG (-)

⁶⁸Ga-DOTATATE PET (+)


^{99m}Tc-TOC (-)

FDG (-) ⁶⁸Ga-DOTATATE PET (+)

A series of translational research work promote MDT for complex, severe and rare diseases



^{18}F -MFBG shows higher sensitivity than ^{131}I -MIBG in staging primary pheochromocytoma and metastasis.



^{177}Lu TATE for patient with advanced GEP NET



Cohort study on insulinoma detection and localization with GLP-1 receptor imaging

Data from PUMCH (~300 patients)



The Journal of
NUCLEAR MEDICINE

Glucagon-Like Peptide-1 Receptor PET/CT with ^{68}Ga -NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study

Yaping Luo, Qingqing Pan, Shaobo Yao, Miao Yu, Wenming Wu, Huadan Xue, Dale O. Kiesewetter, Zhaohui Zhu, Fang Li, Yupei Zhao and Xiaoyuan Chen

	Sen	Spe	Acc	PPV	NPV
^{68}Ga -exendin-4	99.1%	100%	99.4%	100%	98.2%
CT	80.7%	83.7%	81.6%	92.6%	63.2%
MR	78.9%	77.3%	78.6%	92.3%	51.5%
BUS	79.2%	80.0%	79.3%	95.0%	44.4%
SSTR	22.8%	97.9%	47.3%	95.8%	38.1%

Cohort study on insulinoma detection and localization with GLP-1 receptor imaging

Data from PUMCH (~300 patients)


JNM

The Journal of
NUCLEAR MEDICINE

Glucagon-Like Peptide-1 Receptor PET/CT with ^{68}Ga -NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study

Yaping Luo, Qingqing Pan, Shaobo Yao, Miao Yu, Wenming Wu, Huadan Xue, Dale O. Kiesewetter, Zhaohui Zhu, Fang Li, Yupei Zhao and Xiaoyuan Chen

	Sen	Spe	Acc	PPV	NPV
^{68}Ga -exendin-4	99.1%	100%	99.4%	100%	98.2%
CT	80.7%	83.7%	81.6%	92.6%	63.2%
MR	78.9%	77.3%	78.6%	92.3%	51.5%
BUS	79.2%	80.0%	79.3%	95.0%	44.4%
SSTR	22.8%	97.9%	47.3%	95.8%	38.1%




Characterization the functional status of Adrenocortical Masses using CXCR4 receptor imaging



北京协和医院
PEKING UNION MEDICAL COLLEGE HOSPITAL

^{68}Ga -pentixafor PET/CT determine aldosterone-producing adenoma




Characterization the functional status of Adrenocortical Masses using CXCR4 receptor imaging



北京协和医院
PEKING UNION MEDICAL COLLEGE HOSPITAL

^{68}Ga -pentixafor PET/CT determine aldosterone-producing adenoma



Non-invasive NM technology to help diagnose and classify cardiac amyloidosis

^{99m}Tc -PYP were employed for Cardiac amyloidosis diagnosis and classification since 1970s


International journey of NM imaging application in cardiac amyloidosis



PYP 用于诊断 ATTR-CM 的标准流程正式发布


2016年, Bokhari 推荐了 PYP 显像的标准流程, 为今后的应用奠定了技术基础

Table 4. Standardized ^{99m}Tc -PYP imaging protocol	
Procedures	Parameters
Preparation	No fasting required
Scan	Best scan
Dose of ^{99m}Tc -PYP	10 mCi
Time to acquisition	1 hour
Position	Supine
Acquisition and processing	
Camera	Philips Precedence SPECT/CT camera (Philips Healthcare, Guelph, United Kingdom)
Field of view	Large
Detector configuration	90-degrees with a non-circular orbit for 180-degree transit
	Cardiac position with a 45 degree start angle
Energy window	140 keV (20%)
Collimators	Low energy, high resolution
Number of views	Two (Anterior and Lateral)
Image acquisition	750,000 counts
Zoom	1.45
Matrix	256 x 256



Bokhari S, Morgenstern R, Weinberg R, et al. Standardization of ^{99m}Tc pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. J. Journal of Nuclear Cardiology Official Publication of the American Society of Nuclear Cardiology. 2016.

组织活检诊断的 ATTRwt 每年增加, 并在 2014 年达到峰值然后下降, 骨显像诊断 ATTR-CM 显著增加



PYP 显像不断推广逐渐成为诊断 ATTR-CM 重要工具

规范使用 PYP 核素骨扫描诊断 ATTR-CM




北京协和医院
PEKING UNION MEDICAL COLLEGE HOSPITAL

2019.1.25 First international exchange meeting




2019.3.14 Health control imaging




2019.8.30
First patient with wild-type ATTR in China



2020.8 Serve as routine examination project



2020.10
ATTR-CM therapeutic drug approved by CFDA



ATTR-CM临床诊断难点：


2021.12
ATTR-CM therapeutic drug included in NDRL

辉瑞三款创新药纳入国家医保药品目录

2021年12月30日 星期四 | 来源：人微网

12月3日，《国家基本医疗保险、工伤保险和生育保险药品目录》（2021年）正式发布，西药参与谈判的三款创新药均成功纳入：包括治疗非小细胞肺癌表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）的达格芬尼片（商品名：美罗替尼）、治疗非肌层浸润性膀胱癌膀胱源性恶性肿瘤（ATR-CD，简称“达铂方”）的口服药物氟唑秦酰胺注射液（商品名：雅方明）以及用于稳定性冠心病（AD）的无氧酶、外用非甾体类抗炎药的二磷酸二酯酶4（PDE4）抑制剂利伐罗替尼片（商品名：雅方明）。

2021.12
Consensus for ATTR-CM diagnosis with PYP scan



Over 30 speeches for PYP scan promotion

[illegible]

Over 100 hospitals applied PYP scan for ATTR-CM




Development of NM technology to improve ATTRm diagnosis sensitivity and AL-CM risk assessment



北京协和医院
PEKING UNION MEDICAL COLLEGE HOSPITAL

体征 & 症状, 心电图, 超声心动图, 心脏 MRI 提示心脏淀粉样变性




Development of NM technology to improve ATTRm diagnosis sensitivity and AL-CM risk assessment




北京协和医院
PEKING UNION MEDICAL COLLEGE HOSPITAL

体征 & 症状, 心电图, 超声心动图, 心脏 MRI 提示 **心脏淀粉样变性**






⁹⁹Tc^m-PYP SPECT/CT scan

⁹⁹Tc^m-PYP SPECT/CT scan



¹¹C-PIB, ¹⁸F-AV45 PET/CT scan
more sensitive than PYP for ATTRm




Development of NM technology to improve ATTRm diagnosis sensitivity and AL-CM risk assessment




北京协和医院
PEKING UNION MEDICAL COLLEGE HOSPITAL

体征 & 症状, 心电图, 超声心动图, 心脏 MRI 提示 **心脏淀粉样变性**





^{99m}Tc -PYP SPECT/CT scan

^{68}Ga -FAPi for risk assessment




^{99m}Tc -PYP SPECT/CT scan

**^{11}C -PIB, ^{18}F -AV45 PET/CT scan
more sensitive than PYP for ATTRm**



1H, H/CL=1.55

3H, H/CL=1.46



Set up translational corporation platform with clinical department in PUMCH

Hematology, cardiology, endocrinology and neurology department


一、酒精性心肌病

主要合作人:


林雪、方理刚 (心内科)
刘帅 (北京理工大学)
张辉 (清华大学)



国内率先利用PET动态图像计算心肌耗氧量等动力学参数, 发现饮酒与心肌损伤关系



11 C-Acetate



二、心肌淀粉样病变

主要合作人:



田庄、张抒扬 (心内科)
李剑 (血液内科)
王怡宁 (放射科)
许百灵 (美国哥伦比亚大学)




国内率先建立ATTR心肌淀粉样变显像和图像分析方法, 成为科室特色检查项目

- 推广与培训, 在全国建立8个研究中心
- 编写共识;
- 开展高水平科研工作, 解决临床问题

99m Tc-PYP



11 C-PIB



三、原醛所致高血压

主要合作人:

熊家莉、夏维源 (内分泌)
张玉洁、文进、柏志刚 (泌尿外科)



德国慕尼黑工业大学附属右岸医院




68 Ga-CXCR4

由上到下分别为: 肾动脉瘤、结节性增生、无功能腺瘤
截止目前, 已完成患者检查近百例


四、其他心肌病与心衰

主要合作人:

林雪、方理刚、陈杰 (心内科)
杨华毅、郑文浩、张义 (检验科)



68 Ga-DOTATATE




68 Ga-FAPI

五、心脏交感神经显像与PD

主要合作人:


徐月、王会 (神经内科)



六、国产新药临床转化

主要合作人:

林雪、刘国刚、沈晓军 (心内科)
赵祥全、方林 (药理学)
许百灵 (美国哥伦比亚大学)



18F-FMPP2

反映左心室血流灌注

Collaboration with universities, institutions, companies and government for NM translational research in PUMCH



北京协和医院
PEKING UNION MEDICAL COLLEGE HOSPITAL

- Beijing Xiantong International Pharmaceutical Technology Co., Ltd.
- Yantai Dongcheng Biochemicals Co., Ltd.
- Peking university
- Stanford university
- Beijing Normal University
- Fuwai hospital, CAMS.
- Huayi Technology Co., Ltd

Radiopharmaceutical



Nuclide production



CHINA NATIONAL NUCLEAR CORPORATION

PUMCH NM
(图像采集与诊断)

Image data analysis

- Tsinghua University
- Beijing Institute of Technology
- Institute of Automation, Chinese Academy of Sciences
- Nanjing University of Aeronautics and Astronautics
- Medical college of University of Vienna
- Finland national PET center

Quality control



National center for nuclear medicine quality control

Bench to Bed, characteristic of NM translational research work in PUMCH

Strengthening basic research and developing new theranostic tracer for renal cell carcinoma.

